An observational study in Bacterial Infections, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.
Sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Bacterial Infections with a site in China — 10 open to participants now, 10 under way, none of them phase 3. Bacterial Infections · China.
Among the 32 studies in Bacterial Infections with a site in China, this one is the 4th largest by planned enrollment of the 16 observational ones that give a count, is one of 4 that started in 2023, is one of 16 observational ones, and was the 32nd registered.
586 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.
Browse Bacterial Infections studies →10 of the 32 studies in Bacterial Infections with a site in China are open now. Recruiting first, the newest first:
Joincare Pharmaceutical Group Industry Co., Ltd · Sites in China
Ages 18–45 · Healthy volunteers
Eye & ENT Hospital of Fudan University · Sites in China
Ages 18+
The University of Hong Kong · Sites in China
Ages 18–100 · Healthy volunteers
Qilu Hospital of Shandong University · Sites in China
Ages 14+ · Healthy volunteers
Shandong University · Sites in China
Ages up to 18
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 56 Bacterial Infections studies recruiting now, 38 (68%) set no upper age limit and 13 (23%) stop at 75 or younger; 18 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 196 across 186 observational studies indexed under Bacterial Infections.
Median enrollment 259 across the 16 interventional studies, 628 across the 16 observational. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 32 have an industry lead sponsor. The 10 most frequent:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School is the lead sponsor of 251 studies on the registry; 148 are open to participants now.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School has 2 studies filed under Bacterial Infections — fewer than ten, so there is no comparison to draw.
1 of the studies in Bacterial Infections with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07612163The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolClinical Efficacy and Population Pharmacokinetics of β-lactams in Cirrhotic Patients | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies in Bacterial Infections with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Patients may benefit from the personalized β-lactams dosing strategy based on pharmacokinetics. The objective of this study is to retrospectively review, prospective observe and analyze the clinical outcomes of patients with liver cirrhosis, and to build a population pharmacokinetics model in the population mentioned above.
Rational use of β-lactams is closely associated with the clinical outcome of patients with infections. Serum concentration of β-lactams varies from different populations. The objective of this study is to describe the clinical outcome of cirrhotic patients with infection treated by β-lactams in China, regarding diagnosis, treatment and follow-up. It is a single-center, retro-prospective, observational study. Inclusion criteria are an age ≥ 18, liver cirrhosis, diagnosed as bacteria infection and serum concentration must be determined during therapy. Data concerning clinical presentation, biological samples, treatment and follow-up will be assessed. A descriptive analysis will be performed.
Chinese adult cirrhotic patients with bacterial infections treated by β-lactams
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age over 18 years Chinese patient: male or female Liver cirrhosis Diagnosed as bacterial infection Treated by β-lactams Serum concentration determined during therapy
Exclusion Criteria:
Duration of β-lactams treatment less than 48 hours Patients renal or liver function not tested before treatment started Using more than two kinds of β-lactams
Patients with liver cirrhosis or impaired liver function (Child-Pugh grade B or C) treated by β-lactams
Drug: β-lactams
Participants receiving β-lactams were included.
Mortality
30-day mortality and 90-day mortality
Time frame: January 2018-December 2026
Serum concentrations
Serum concentrations of β-lactams
Time frame: January 2018-December 2026
Proportion of patients reach clinical response at end of treatment
By definition, a successful clinical response means resolution of clinically significant signs and symptoms(defined as any criteria of systemic inflammatory response syndrome, body temperature over 38℃ or below 36℃, blood white cell count more than 12\*10\^9/L or less than 4\*10\^9/L, respiratory rate faster than 20 times per minute and heart rate higher than 90 beats per minute) or partial resolution of clinically significant signs and symptoms
Time frame: January 2018-December 2026
Proportion of patients reach clinical response at day 4 of treatment
By definition, a successful clinical response means resolution of clinically significant signs and symptoms(defined as any criteria of systemic inflammatory response syndrome, body temperature over 38℃ or below 36℃, blood white cell count more than 12\*10\^9/L or less than 4\*10\^9/L, respiratory rate faster than 20 times per minute and heart rate higher than 90 beats per minute) or partial resolution of clinically significant signs and symptoms
Time frame: January 2018-December 2026
Daily Sequential Organ Failure Assessment score change
Sequential Organ Failure Assessment score (Range from 0-24), lower score means a better outcome. Increase of 2 points within 48 hours means the presence of sepsis.
Time frame: January 2018-December 2026
Incidence of Septic Shock
Incidence of Septic Shock
Time frame: January 2018-December 2026
Safety outcome measures
Safety outcome measures including nephrotoxicity, hepatotoxicity and other adverse events related to the antibiotic treatment of β-lactams
Time frame: January 2018-December 2026
Plan to share: Undecided
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.
Of 74 non-industry observational studies under Bacterial Infections, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 36 months is above that.
Counting every sponsor, half of 81 studies reached it within 22 months; a quarter within 12 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School →